Country: United States
Language: English
Source: NLM (National Library of Medicine)
Atropine Sulfate (UNII: 03J5ZE7KA5) (Atropine - UNII:7C0697DR9I)
General Injectables & Vaccines, Inc.
Atropine Sulfate
Atropine Sulfate .05 mg in 1 mL
INTRAMUSCULAR
PRESCRIPTION DRUG
Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. None. 8.1 Pregnancy Animal reproduction studies have not been conducted with atropine. It also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. 8.3 Nursing Mothers Trace amounts of atropine was found in breast milk. The clinical impact of this is not known. 8.5 Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Atropine Sulfate Injection, USP is supplied in single-dose containers as follows: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). [See USP Controlled Room Temperature.] Distributed by Hospira, Inc., Lake Forest, IL 60045 USA LAB-1041-3.0
New Drug Application
ATROPINE SULFATE - ATROPINE SULFATE INJECTION, SOLUTION GENERAL INJECTABLES & VACCINES, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION PEDIATRIC ATROPINE SULFATE, INJECTION USP 0.25MG/5ML HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ATROPINE SULFATE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ATROPINE SULFATE INJECTION. ATROPINE SULFATE INJECTION, FOR INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS OR ENDOTRACHEAL USE. INITIAL U.S. APPROVAL: 1960 INDICATIONS AND USAGE Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life threatening muscarinic effects. (1) (2) DOSAGE AND ADMINISTRATION For intravenous administration, but may also be administered via subcutaneous, intramuscular or via an endotracheal tube (2.1, 2.3). Titrate according to heart rate, PR interval, blood pressure and symptoms. (2.1) Adult dosage Antisialagogue or for antivagal effects: Initial single dose of 0.5 mg to 1 mg (2.2) Antidote for organophosphorus or muscarinic mushroom poisoning: Initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes. (2.2) Bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists. (2.2) Patients with Coronary Artery Disease: Limit the total dose to 0.03 mg/kg to 0.04 mg/kg. (2.4) DOSAGE FORMS AND STRENGTHS 0.05 mg/mL injection in Ansyr Plastic Syringe (3) 0.1 mg/mL injection in Ansyr Plastic Syring (3) CONTRAINDICATIONS None. (5) WARNINGS AND PRECAUTIONS Tachycardia (5.1) (6) Glaucoma (5.2) (6) Pyloric obstruction (5.3) (6) Worsening urinary retention (5.4) (6) Vascid bronchial plugs (5.5) (6) ADVERSE REACTIONS Most adverse reactions are directly related to atopine's antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur with chronic administreation of therepeutic doses. (6) (7) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT HOSPIRA, INC. AT 1-800-441-4100, OR FDA AT 1-800-FDA-1088 OR _WWW.FDA.GOV/MEDWA Read the complete document